Plant Name: Symplocos setchuensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR2C; ADRA2C; ADRA2A; ADRA2B; HTR6; | |
| NPSR1; | |
| CSNK1D; PIM3; DYRK1B; DYRK2; CLK1; DYRK3; DYRK1A; HASPIN; | |
| MAOA; | |
| ALDH1A1; | |
| HIF1A; NFKB1; | |
| SLC6A2; | |
| NISCH; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | CSNK1D | Casein kinase I delta | P48730 | CHEMBL2828 |
| Protein Kinase | PIM3 | Serine/threonine-protein kinase PIM3 | Q86V86 | CHEMBL5407 |
| Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
| Protein Kinase | DYRK2 | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Q92630 | CHEMBL4376 |
| Protein Kinase | CLK1 | Dual specificty protein kinase CLK1 | P49759 | CHEMBL4224 |
| Protein Kinase | DYRK3 | Dual-specificity tyrosine-phosphorylation regulated kinase 3 | O43781 | CHEMBL4575 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | NISCH | Nischarin | Q9Y2I1 | CHEMBL3923 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.436E-09 | 2.149E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 2.960E-09 | 2.149E-05 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 9.733E-09 | 4.239E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 9.733E-09 | 4.239E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.857E-08 | 1.058E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.358E-07 | 2.075E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.291E-07 | 2.075E-04 | CLK1, CSNK1D, DYRK1A, DYRK1B, DYRK2, DYRK3, HASPIN, PIM3 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.358E-07 | 2.075E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.313E-07 | 6.806E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 2.733E-06 | 2.204E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.834E-06 | 2.899E-03 | HTR2C, HTR6, HTR7 |
| BP | Unclassified; | GO:0098664; G-protein coupled serotonin receptor signaling pathway | 4.834E-06 | 2.899E-03 | HTR2C, HTR6, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.899E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004713; protein tyrosine kinase activity | 4.668E-06 | 2.899E-03 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.834E-06 | 2.899E-03 | HTR2C, HTR6, HTR7 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 5.332E-06 | 3.056E-03 | CLK1, DYRK1A, DYRK1B, DYRK2, DYRK3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 3.138E-03 | CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0015874; norepinephrine transport | 1.127E-05 | 5.221E-03 | NISCH, SLC6A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.127E-05 | 5.221E-03 | CYP1A2, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.416E-05 | 6.166E-03 | ADRA2A, ADRA2B, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.683E-07 | 3.241E-05 | HTR6; HTR7; CYP2D6; MAOA; HTR2C |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.550E-06 | 6.290E-05 | HTR6; HTR7; HTR2C; ADRA2C; ADRA2B; ADRA2A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.144E-06 | 6.290E-05 | MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.064E-05 | 1.994E-03 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.281E-04 | 2.255E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.443E-03 | 1.588E-02 | ADRA2C; ADRA2B; ADRA2A |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.789E-03 | 1.747E-02 | HTR6; HTR7; HTR2C |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.326E-03 | 1.588E-02 | MAOA; CYP1A2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.967E-04 | 1.022E-02 | CYP1A2; CYP3A4 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.985E-03 | 1.747E-02 | MAOA; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.494E-03 | 1.995E-02 | CLK1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.769E-03 | 2.031E-02 | CYP1A2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.255E-03 | 3.932E-02 | HTR2C; CSNK1D |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.454E-03 | 3.692E-02 | CYP1A2; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.477E-03 | 4.663E-02 | HIF1A; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.732E-03 | 3.950E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; NFKB1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; ADRA2B; MAOA; HTR2C |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; SLC6A2; MAOA; MAOA; HTR2C; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAOA; MAPT; HTR6; HTR6; HTR6 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; HTR2C; HTR6 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; HTR6 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; SLC6A2; HTR2C; HTR2C; HTR6 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; SLC6A2; HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| NA: NA | Primary insomnia | NA | HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR2C; HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA; HTR2C; HTR6; HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |